Valneva

Valneva EBIT Margin

The EBIT Margin (Operating Margin) of Valneva (VLA.PA) as of Sep 17, 2026 is -46.74 %. In the previous year, EBIT Margin (Operating Margin) was 7.86 % — a change of -694.57% (lower).

EBIT Margin

-46.74 %

YoY

-694.57%

Last updated:

EBIT Margin (Operating Margin) of Valneva is 2026 -46.74 % . EBIT Margin (Operating Margin) of Valneva was 2025 7.86 % . It decreases by -694.57% lower compared to the previous year.

For Valneva, the operating (EBIT) margin of -46.7% is down versus -15.3% a few years ago.

The Valneva EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
5.54 EUR
Jan 1, 2019
1.19 EUR
Jan 1, 2020
-49.57 EUR
Jan 1, 2021
-15.30 EUR
Jan 1, 2022
-34.88 EUR
Jan 1, 2023
-49.78 EUR
Jan 1, 2024
7.86 EUR
Jan 1, 2025
-46.74 EUR
The Valneva EBIT Margin history
YEAREBIT MarginYoY
-46.74 %-694.57%
7.86 %-115.79%
-49.78 %+42.71%
-34.88 %+127.94%
-15.30 %-69.13%
-49.57 %-4,261.72%
1.19 %-78.50%
5.54 %-247.50%
-3.76 %-91.74%
-45.44 %+78.62%
-25.44 %-60.56%
-64.50 %+9,316.19%
-0.69 %-81.68%
-3.74 %+762.43%
-0.43 %-56.74%
-1.00 %-50.69%
-2.03 %+120.35%
-0.92 %-83.30%
-5.53 %+5,722.93%
-0.09 %
Access this data via the Eulerpool API

Valneva Stock analysis

What does Valneva do? Valneva SE is a biopharmaceutical company specializing in the development, production, and marketing of vaccines for humans and animals. The company was founded in 2013 through the merger of French biotech company Vivalis and Austrian biotech company Intercell. Valneva focuses on developing vaccines for infectious diseases with a significant global burden but limited commercial demand. They work closely with governments and international organizations to improve access to their vaccines in developing countries. Valneva also has a strong presence in the animal vaccine market, producing vaccines for diseases in livestock and pets. They have developed and marketed several vaccines, including Ixiaro for Japanese encephalitis and VLA15, a vaccine candidate for Lyme disease. Overall, Valneva is an international company with an impressive pipeline of vaccine candidates and a commitment to addressing global health needs. Valneva is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valneva stock

EBIT Margin (Operating Margin) of Valneva is -46.74 % in 2026.

EBIT Margin (Operating Margin) of Valneva changed from 7.86 % to -46.74 %, representing a -694.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Valneva since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Valneva with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

Margins — Valneva

All Key Metrics — Valneva